ID   BCBL-1
AC   CVCL_0165
SY   BCBL1; BCBL; Body Cavity Based Lymphoma-1
DR   BTO; BTO:0002727
DR   EFO; EFO_0002048
DR   MCCL; MCC:0000057
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473436
DR   BioSamples; SAMEA365914
DR   BioSamples; SAMEA365927
DR   cancercelllines; CVCL_0165
DR   Cosmic; 1238078
DR   Cosmic; 1515185
DR   Cosmic; 1588560
DR   DSMZ; ACC-683
DR   DSMZCellDive; ACC-683
DR   GEO; GSM33134
DR   GEO; GSM38800
DR   GEO; GSM38801
DR   GEO; GSM634735
DR   GEO; GSM710421
DR   GEO; GSM710437
DR   GEO; GSM1265856
DR   GEO; GSM1265857
DR   GEO; GSM1265858
DR   GEO; GSM1265859
DR   GEO; GSM1265860
DR   GEO; GSM1265868
DR   GEO; GSM3150238
DR   HIVReagentProgram; ARP-3233
DR   IARC_TP53; 26980
DR   Lonza; 238
DR   PRIDE; PXD012087
DR   Progenetix; CVCL_0165
DR   TOKU-E; 4070
DR   Wikidata; Q54795334
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8612236;
RX   PubMed=9375005;
RX   PubMed=9766492;
RX   PubMed=15613351;
RX   PubMed=17121789;
RX   PubMed=17324269;
RX   PubMed=19521981;
RX   PubMed=19608668;
RX   PubMed=21685375;
RX   PubMed=28196595;
RX   PubMed=31160637;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=BCBL-1
WW   https://tcpaportal.org/mclp/
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: ~50 hours (DSMZ=ACC-683).
CC   HLA typing: A*01:01:01,31:01:02; B*51:01:01,55:01:01; C*03:03:01,15:02:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,04:01:01; DQA1*01:02:01,01:04:01; DQB1*05:03:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*14:54:01,15:01:01 (DSMZCellDive=ACC-683).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>A); ClinVar=VCV000480961; Zygosity=Heterozygous (PubMed=17121789).
CC   Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 12
ST   D18S51: 13
ST   D19S433: 14
ST   D21S11: 29,30
ST   D2S1338: 19,25
ST   D3S1358: 16,17
ST   D5S818: 11,13
ST   D7S820: 8,9
ST   D8S1179: 16
ST   FGA: 20,22
ST   Penta D: 9,13
ST   Penta E: 14
ST   TH01: 9,9.3
ST   TPOX: 9
ST   vWA: 17
DI   NCIt; C6915; Primary effusion lymphoma
DI   ORDO; Orphanet_48686; Primary effusion lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   40Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 27
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8612236; DOI=10.1038/nm0396-342;
RA   Renne R., Zhong W.-D., Herndier B.G., McGrath M.S., Abbey N.W.,
RA   Kedes D.H., Ganem D.E.;
RT   "Lytic growth of Kaposi's sarcoma-associated herpesvirus (human
RT   herpesvirus 8) in culture.";
RL   Nat. Med. 2:342-346(1996).
//
RX   PubMed=9375005; DOI=10.1006/viro.1997.8822;
RA   Picchio G.R., Sabbe R.E., Gulizia R.J., McGrath M.S., Herndier B.G.,
RA   Mosier D.E.;
RT   "The KSHV/HHV8-infected BCBL-1 lymphoma line causes tumors in SCID
RT   mice but fails to transmit virus to a human peripheral blood
RT   mononuclear cell graft.";
RL   Virology 238:22-29(1997).
//
RX   PubMed=9766492; DOI=10.1038/sj.leu.2401160;
RA   Drexler H.G., Uphoff C.C., Gaidano G., Carbone A.;
RT   "Lymphoma cell lines: in vitro models for the study of HHV-8+ primary
RT   effusion lymphomas (body cavity-based lymphomas).";
RL   Leukemia 12:1507-1517(1998).
//
RX   PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005;
RA   Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E.,
RA   Knowles D.M.;
RT   "Distinct subsets of primary effusion lymphoma can be identified based
RT   on their cellular gene expression profile and viral association.";
RL   J. Virol. 79:1244-1251(2005).
//
RX   PubMed=17121789; DOI=10.1128/JVI.01757-06;
RA   Burd C.E., Sin S.-H., Dittmer D.P.;
RT   "Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus
RT   lymphomas: implications for therapy.";
RL   J. Virol. 81:1912-1922(2007).
//
RX   PubMed=17324269; DOI=10.1186/1471-2407-7-35;
RA   Ruff K.R., Puetter A., Levy L.S.;
RT   "Growth regulation of simian and human AIDS-related non-Hodgkin's
RT   lymphoma cell lines by TGF-beta1 and IL-6.";
RL   BMC Cancer 7:35.1-35.13(2007).
//
RX   PubMed=19521981; DOI=10.1002/ijc.24521;
RA   Takahashi-Makise N., Suzu S., Hiyoshi M., Ohsugi T., Katano H.,
RA   Umezawa K., Okada S.;
RT   "Biscoclaurine alkaloid cepharanthine inhibits the growth of primary
RT   effusion lymphoma in vitro and in vivo and induces apoptosis via
RT   suppression of the NF-kappaB pathway.";
RL   Int. J. Cancer 125:1464-1472(2009).
//
RX   PubMed=19608668; DOI=10.3324/haematol.2009.007260;
RA   Boulanger E., Marchio A., Hong S.-S., Pineau P.;
RT   "Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin
RT   genes in human herpesvirus 8-associated primary effusion lymphoma.";
RL   Haematologica 94:1170-1174(2009).
//
RX   PubMed=21685375; DOI=10.1182/blood-2010-12-323659;
RA   Roy D., Sin S.-H., Damania B., Dittmer D.P.;
RT   "Tumor suppressor genes FHIT and WWOX are deleted in primary effusion
RT   lymphoma (PEL) cell lines.";
RL   Blood 118:E32-E39(2011).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//